Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases”

45 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 45 results

Testing effectiveness (Phase 2)Ended earlyNCT04639024
What this trial is testing

ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Myeloproliferative Neoplasm (MDS/MPN)
Gwynn Long, M.D. 3
Testing effectiveness (Phase 2)Looking for participantsNCT06892223
What this trial is testing

Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation

Who this might be right for
Acute Myeloid LeukaemiaMDS (Myelodysplastic Syndrome)MPN (Myeloproliferative Neoplasms)
Istituto Clinico Humanitas 42
Testing effectiveness (Phase 2)Active Not RecruitingNCT05732961
What this trial is testing

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

Who this might be right for
Myelodysplastic SyndromesMyeloproliferative NeoplasmAnemia
H. Lee Moffitt Cancer Center and Research Institute 6
Not applicableStudy completedNCT02775383
What this trial is testing

The National Myelodysplastic Syndromes (MDS) Study

Who this might be right for
Myelodysplastic Syndromes (MDS)
National Heart, Lung, and Blood Institute (NHLBI) 2,115
Early research (Phase 1)Ended earlyNCT01066468
What this trial is testing

Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

Who this might be right for
Chronic Myeloid Leukemia (CML)Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)
Novartis Pharmaceuticals 3
Testing effectiveness (Phase 2)WithdrawnNCT05927012
What this trial is testing

Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).

Who this might be right for
Iron Deficiency Anemia
Keros Therapeutics, Inc.
Testing effectiveness (Phase 2)Study completedNCT03238248
What this trial is testing

Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors

Who this might be right for
Myelodysplastic SyndromesMyeloproliferative Neoplasm
Vanderbilt-Ingram Cancer Center 71
Early research (Phase 1)Study completedNCT05665530
What this trial is testing

PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Who this might be right for
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Mantle Cell Lymphoma (MCL)+9 more
Prelude Therapeutics Incorporated 86
Early research (Phase 1)Active Not RecruitingNCT04603001
What this trial is testing

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Who this might be right for
Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Chronic Myelomonocytic Leukemia (CMML)+1 more
Eli Lilly and Company 260
Testing effectiveness (Phase 2)Active Not RecruitingNCT05600894
What this trial is testing

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Who this might be right for
Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromeMyelodysplastic Syndrome With Excess Blasts+2 more
National Cancer Institute (NCI) 132
Early research (Phase 1)Looking for participantsNCT04771572
What this trial is testing

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Who this might be right for
Non Hodgkin LymphomaRichter TransformationMultiple Myeloma+10 more
Newave Pharmaceutical Inc 100
Early research (Phase 1)Study completedNCT04473911
What this trial is testing

Haplo Peripheral Blood Sct In GVHD Prevention

Who this might be right for
GVHDAMLALL+13 more
Zachariah Michael DeFilipp 25
Early research (Phase 1)Ended earlyNCT04637009
What this trial is testing

TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

Who this might be right for
Acute Myeloid LeukemiaMyeloproliferative NeoplasmMyelodysplastic/Myeloproliferative Neoplasm
Astex Pharmaceuticals, Inc. 20
Early research (Phase 1)Ended earlyNCT05609942
What this trial is testing

Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

Who this might be right for
Advanced Systemic Mastocytosis
Blueprint Medicines Corporation 9
Testing effectiveness (Phase 2)Study completedNCT01606579
What this trial is testing

Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies

Who this might be right for
Acute Myeloid LeukemiaChronic Myeloid Leukemia
Prism Pharma Co., Ltd. 49
Testing effectiveness (Phase 2)Study completedNCT03072043
What this trial is testing

Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms

Who this might be right for
Myelodysplastic SyndromeAcute Myeloid LeukemiaMyeloproliferative Neoplasm+1 more
H. Lee Moffitt Cancer Center and Research Institute 55
Early research (Phase 1)Ended earlyNCT02663518
What this trial is testing

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Who this might be right for
Hematologic MalignanciesSolid Tumor
Pfizer 249
Testing effectiveness (Phase 2)Ended earlyNCT02431260
What this trial is testing

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

Who this might be right for
Solid Tumors and Hematologic Malignancy
Incyte Corporation 69
Large-scale testing (Phase 3)Looking for participantsNCT04064060
What this trial is testing

Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Who this might be right for
Myelodysplastic Syndromes (MDS)Beta-thalassemiaMyeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
Celgene 665
Testing effectiveness (Phase 2)Ended earlyNCT05005182
What this trial is testing

Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts

Who this might be right for
Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise SpecifiedMyelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified
Mayo Clinic 3
Next Page